Download video

How To Increase Your Borrowing Capacity, in 2025 | Ep. 21 ft. Michael Killiner

106 views

The Follio Property Podcast

10 months ago

How To Increase Your Borrowing Capacity, in 2025 | Ep. 21 ft. Michael Killiner

How To Increase Your Borrowing Capacity, in 2025 | Ep. 21 ft. Michael Killiner

Prognostic value of intrinsic subtypes in HR+\/HER2- breast cancer after CDK4\/6 inhibitors
3:07
Prognostic value of intrinsic subtypes in HR+\/HER2- breast cancer after CDK4\/6 inhibitors
by VJOncology
202510141508
3:21
202510141508
by Informatics
Endocrine Society: Q2 Results and Q3 Highlights of 2025
1:15
Endocrine Society: Q2 Results and Q3 Highlights of 2025
by Endocrine Society
Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence
1:11
Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence
by Targeted Oncology
Q2
7:01
Q2
by HoungJunHongBiology
RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
1:33
RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
by VJOncology
Is T2 the answer?
10:01
Is T2 the answer?
by Dr. Eric Balcavage
I Survived Lung Cancer
44:33
I Survived Lung Cancer
by Dr. Debbie Ozment
Kidney Cancer Breakout: New treatments to preserve quality of life
30:21
Kidney Cancer Breakout: New treatments to preserve quality of life
by Cancer Research Institute
Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma
0:36
Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma
by VJHemOnc – Video Journal of Hematology \& HemOnc
H2 Metabolism and ageing
6:41
H2 Metabolism and ageing
by Dr Vannthoeun Ung
Brightline-2: brigimadlin as a 2L treatment for advanced cancers with MDM2 amplification and wtTP53
1:34
Brightline-2: brigimadlin as a 2L treatment for advanced cancers with MDM2 amplification and wtTP53
by VJOncology
RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC
8:42
RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC
by GU Oncology Now
A Phase II trial of mosunetuzumab plus polatuzumab vedotin in R\/R LBCL
1:33
A Phase II trial of mosunetuzumab plus polatuzumab vedotin in R\/R LBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis
2:17
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis
by VJHemOnc – Video Journal of Hematology \& HemOnc
B-cell lymphoma 2 mediated regulation protects growth plate cartilage
1:28
B-cell lymphoma 2 mediated regulation protects growth plate cartilage
by AJE Video Bytes